ARPA-H Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE)

The GLIDE program is run by Kimberley Steele, “envisions a future where doctors have a wide variety of therapeutic tools targeting abnormal lymphatic structure and function. Such treatments could prevent and cure primary lymphatic disease and other chronic disorders associated with lymphatic dysfunction, like autoimmune disorders and cancers. GLIDE aims to advance lymphatic medicine, improve our understanding of the role of lymphatic dysfunction in disease, and build effective, affordable, and accessible treatment options.” There’s a hybrid Proposers’ Day coming up on September 17.